Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

Jiao Liu(Nanfang Hospital), Dechang Chen(Shanghai Jiao Tong University), Yanxia Huang(Shanghai Jiao Tong University), Qiang Zhao(Commercial Aircraft Corporation of China (China)), Xiangdong Guan(Xinjiang Medical University), Quanhong Zhou(Shanghai Jiao Tong University), Yun Ling(Zhejiang Chinese Medical University), Zhenliang Wen(Shanghai Jiao Tong University), Xiaofei Ye(Second Military Medical University), Lidi Zhang(Shanghai Jiao Tong University), Yunfeng Wang(Shanghai University of Medicine and Health Sciences), Jieming Qu(Shanghai Jiao Tong University), Zhijie Xia(Fudan University), Lun–Xiu Qin(Huashan Hospital), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Djillali Annane(Hôpital Raymond-Poincaré), Hangxiang Du(Shanghai Jiao Tong University), Zi Ge(Fudan University), Ying Lv(Shanxi Medical University), Xiaojun Pan(Wenzhou Medical University), Xingqi Deng(Shanghai University of Medicine and Health Sciences), Ming Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xian Zhang(AST Products (United States)), Tao Wang(Shanghai Jiao Tong University), Wenzhe Li(Shanghai Jiao Tong University), Yi Yang(Hebei Medical University), Ke Ma(The Eighth Hospital of Xi'an), Sisi Huang(Shanghai Jiao Tong University), Ren Zhao(Shanghai Institute of Hematology), Sheng Zhang(Shanghai East Hospital), Yizhu Chen(Shanghai Jiao Tong University), Tangkai Qi(Shanghai Public Health Clinical Center), Yongan Liu(Shanghai Jiao Tong University), Cunyi Fan(Shanghai Sixth People's Hospital)
The Lancet Regional Health - Western Pacific
February 5, 2023
Cited by 112


Related Papers